S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Wall Street Legend Warns "Mass Bank Run" is Coming (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Wall Street Legend Warns "Mass Bank Run" is Coming (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Wall Street Legend Warns "Mass Bank Run" is Coming (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Wall Street Legend Warns "Mass Bank Run" is Coming (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
66,000% upside on tiny biotech? (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Leading Egyptian opposition politician targeted with spyware, researchers find
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Forecast, Price & News

$1.77
+0.02 (+1.14%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.74
$1.81
50-Day Range
$1.61
$2.54
52-Week Range
$1.12
$3.52
Volume
14.90 million shs
Average Volume
21.14 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Ginkgo Bioworks MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
111.9% Upside
$3.75 Price Target
Short Interest
Bearish
16.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Ginkgo Bioworks in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.69 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.35) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

737th out of 965 stocks

Biological Products, Except Diagnostic Industry

118th out of 160 stocks


DNA stock logo

About Ginkgo Bioworks (NYSE:DNA) Stock

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Price History

DNA Stock News Headlines

The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Ginkgo Bioworks (NYSE:DNA) Trading Down 4.9% on Insider Selling
Ginkgo Bioworks (NYSE:DNA) Shares Gap Down on Insider Selling
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks to Host Investor Day on October 3, 2023
BTIG Keeps Their Buy Rating on Ginkgo Bioworks Holdings (DNA)
Berenberg Bank Remains a Buy on Ginkgo Bioworks Holdings (DNA)
Why Ginkgo Bioworks Stock Is Climbing Tuesday
Ginkgo Bioworks: Lack Of Progress Is A Concern
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Company Calendar

Last Earnings
8/09/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,292
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+111.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-2,104,930,000.00
Net Margins
-375.48%
Pretax Margin
-379.24%

Debt

Sales & Book Value

Annual Sales
$477.71 million
Book Value
$0.89 per share

Miscellaneous

Outstanding Shares
2,098,850,000
Free Float
1,782,976,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.17
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jason Kelly (Age 42)
    Founder, CEO & Director
    Comp: $262.5k
  • Dr. Reshma P. Shetty (Age 42)
    Founder, Pres, COO & Director
    Comp: $262.5k
  • Mr. Mark E. Dmytruk (Age 52)
    Chief Financial Officer
    Comp: $465.25k
  • Mr. Thomas Knight Jr.
    Founder
  • Mr. Austin Che
    Founder, Head of Strategy & Treasurer
  • Mr. Bartholomew Canton
    Founder, CTO & Sec.
  • Mr. Steven P. Coen CPA
    Chief Accounting Officer
  • Karen Tepichin
    Gen. Counsel & Sec.
  • Ms. Anna Marie Wagner
    Sr. VP of Corp. Devel.
  • Ms. Samantha Sutton
    Head of People













DNA Stock - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price forecast for 2023?

5 equities research analysts have issued twelve-month target prices for Ginkgo Bioworks' stock. Their DNA share price forecasts range from $1.25 to $6.00. On average, they expect the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2023?

Ginkgo Bioworks' stock was trading at $1.69 at the beginning of 2023. Since then, DNA stock has increased by 4.7% and is now trading at $1.77.
View the best growth stocks for 2023 here
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our DNA earnings forecast
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.09) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.09). The business had revenue of $80.57 million for the quarter, compared to analyst estimates of $70.41 million. Ginkgo Bioworks had a negative net margin of 375.48% and a negative trailing twelve-month return on equity of 66.58%.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $245.00 million-$260.00 million, compared to the consensus revenue estimate of $292.83 million.

What is Ginkgo Bioworks' stock symbol?

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.56%), ARK Investment Management LLC (8.14%), BlackRock Inc. (3.27%), Sumitomo Mitsui Trust Holdings Inc. (2.44%), State Street Corp (0.99%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ginkgo Bioworks' stock price today?

One share of DNA stock can currently be purchased for approximately $1.77.

How much money does Ginkgo Bioworks make?

Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.71 billion and generates $477.71 million in revenue each year. The company earns $-2,104,930,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How many employees does Ginkgo Bioworks have?

The company employs 1,292 workers across the globe.

How can I contact Ginkgo Bioworks?

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.

This page (NYSE:DNA) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -